Randi J Hagerman1, Jonathan Polussa. 1. aMedical Investigation of Neurodevelopmental Disorders (MIND) Institute bDepartment of Pediatrics, University of California Davis Health System, Sacramento, California, USA.
Abstract
PURPOSE OF REVIEW: This work reviews recent research regarding treatment of fragile X syndrome (FXS), the most common inherited cause of intellectual disability and autism spectrum disorder. The phenotype includes anxiety linked to sensory hyperarousal, hyperactivity, and attentional problems consistent with attention deficit hyperactivity disorder and social deficits leading to autism spectrum disorder in 60% of boys and 25% of girls with FXS. RECENT FINDINGS: Multiple targeted treatments for FXS have rescued the phenotype of the fmr1 knockout mouse, but few have been beneficial to patients with FXS. The failure of the metabotropic glutamate receptor 5 antagonists falls on the heels of the failure of Arbaclofen's efficacy in children and adults with autism or FXS. In contrast, efficacy has been demonstrated in a controlled trial of minocycline in children with FXS. Minocycline lowers the abnormally elevated levels of matrix metalloproteinase 9 in FXS. Acamprosate and lovastatin have been beneficial in open-label trials in FXS. The first 5 years of life may be the most efficacious time for intervention when combined with behavioral and/or educational interventions. SUMMARY: Minocycline, acamprosate, lovastatin, and sertraline are treatments that can be currently prescribed and have shown benefit in children with FXS. Use of combined medical and behavioral interventions will likely be most efficacious for the treatment of FXS.
PURPOSE OF REVIEW: This work reviews recent research regarding treatment of fragile X syndrome (FXS), the most common inherited cause of intellectual disability and autism spectrum disorder. The phenotype includes anxiety linked to sensory hyperarousal, hyperactivity, and attentional problems consistent with attention deficit hyperactivity disorder and social deficits leading to autism spectrum disorder in 60% of boys and 25% of girls with FXS. RECENT FINDINGS: Multiple targeted treatments for FXS have rescued the phenotype of the fmr1 knockout mouse, but few have been beneficial to patients with FXS. The failure of the metabotropic glutamate receptor 5 antagonists falls on the heels of the failure of Arbaclofen's efficacy in children and adults with autism or FXS. In contrast, efficacy has been demonstrated in a controlled trial of minocycline in children with FXS. Minocycline lowers the abnormally elevated levels of matrix metalloproteinase 9 in FXS. Acamprosate and lovastatin have been beneficial in open-label trials in FXS. The first 5 years of life may be the most efficacious time for intervention when combined with behavioral and/or educational interventions. SUMMARY:Minocycline, acamprosate, lovastatin, and sertraline are treatments that can be currently prescribed and have shown benefit in children with FXS. Use of combined medical and behavioral interventions will likely be most efficacious for the treatment of FXS.
Authors: Inge Heulens; Michael Suttie; Andrei Postnov; Nora De Clerck; Concetta S Perrotta; Teresa Mattina; Francesca Faravelli; Francesca Forzano; R Frank Kooy; Peter Hammond Journal: Eur J Hum Genet Date: 2012-12-05 Impact factor: 4.246
Authors: Rajaa el Bekay; Yanina Romero-Zerbo; Juan Decara; Lourdes Sanchez-Salido; Ignacio Del Arco-Herrera; Fernando Rodríguez-de Fonseca; Yolanda de Diego-Otero Journal: Eur J Neurosci Date: 2007-11-14 Impact factor: 3.386
Authors: Harpreet Sidhu; Lorraine E Dansie; Peter W Hickmott; Douglas W Ethell; Iryna M Ethell Journal: J Neurosci Date: 2014-07-23 Impact factor: 6.167
Authors: Craig A Erickson; Balmiki Ray; Bryan Maloney; Logan K Wink; Katherine Bowers; Tori L Schaefer; Christopher J McDougle; Deborah K Sokol; Debomoy K Lahiri Journal: J Psychiatr Res Date: 2014-08-19 Impact factor: 4.791
Authors: Luigi Boccuto; Chin-Fu Chen; Ayla R Pittman; Cindy D Skinner; Heather J McCartney; Kelly Jones; Barry R Bochner; Roger E Stevenson; Charles E Schwartz Journal: Mol Autism Date: 2013-06-03 Impact factor: 7.509
Authors: Rick M Tankard; Mark F Bennett; Peter Degorski; Martin B Delatycki; Paul J Lockhart; Melanie Bahlo Journal: Am J Hum Genet Date: 2018-11-29 Impact factor: 11.025
Authors: Walter E Kaufmann; Sharon A Kidd; Howard F Andrews; Dejan B Budimirovic; Amy Esler; Barbara Haas-Givler; Tracy Stackhouse; Catharine Riley; Georgina Peacock; Stephanie L Sherman; W Ted Brown; Elizabeth Berry-Kravis Journal: Pediatrics Date: 2017-06 Impact factor: 7.124
Authors: Weixiang Guo; Eric D Polich; Juan Su; Yu Gao; Devin M Christopher; Andrea M Allan; Min Wang; Feifei Wang; Guangfu Wang; Xinyu Zhao Journal: Cell Rep Date: 2015-06-04 Impact factor: 9.423
Authors: Yue Li; Michael E Stockton; Ismat Bhuiyan; Brian E Eisinger; Yu Gao; Jessica L Miller; Anita Bhattacharyya; Xinyu Zhao Journal: Sci Transl Med Date: 2016-04-27 Impact factor: 17.956
Authors: Stephen M Ostrowski; Kachael Johnson; Matthew Siefert; Sam Shank; Luigi Sironi; Benjamin Wolozin; Gary E Landreth; Assem G Ziady Journal: Neuroscience Date: 2016-05-12 Impact factor: 3.590
Authors: Eleanor M Eckert; Kelli C Dominick; Ernest V Pedapati; Logan K Wink; Rebecca C Shaffer; Howard Andrews; Tse-Hwei Choo; Chen Chen; Walter E Kaufmann; Nicole Tartaglia; Elizabeth M Berry-Kravis; Craig A Erickson Journal: J Autism Dev Disord Date: 2019-11